LIPID A MODIFICATION SYSTEMS IN GRAM-NEGATIVE BACTERIA

Christian R.H. Raetz[1,2], **C. Michael Reynolds**[1], **M. Stephen Trent**[3], and **Russell E. Bishop**[4]

1*Department of Biochemistry, Duke University Medical Center, P.O. Box 3711, Durham, North Carolina 27710*

3*Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia 30912*

4*Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada L8N 3Z5*

Abstract

The lipid A moiety of lipopolysaccharide forms the outer monolayer of the outer membrane of most Gram-negative bacteria. *Escherichia coli* lipid A is synthesized on the cytoplasmic surface of the inner membrane by a conserved pathway of nine constitutive enzymes. Following attachment of the core oligosaccharide, lipid A is flipped to the outer surface of the inner membrane by the ABC transporter MsbA, where the O-antigen polymer is attached. Diverse covalent modifications of lipid A may occur during its transit from the outer surface of the inner membrane to the outer membrane. Lipid A modification enzymes are therefore reporters for LPS trafficking within the bacterial cell envelope. Modification systems are highly variable and are often regulated by environmental conditions. Although not required for growth, the modification enzymes modulate the virulence of some Gram-negative pathogens. Heterologous expression of the genes encoding the lipid A modification enzymes in diverse bacteria facilitates the re-engineering of lipid A structures and should enable the development of new vaccines.

INTRODUCTION

Bacterial outer membranes

Lipid A (endotoxin), the hydrophobic anchor of lipopolysaccharide (LPS), is a glucosamine-based saccharolipid (1) that makes up the outer monolayer of the outer membranes of most Gram-negative bacteria (2-4). There are approximately 10^6 lipid A residues, 10^7 phospholipids and 10^5 undecaprenyl phosphate-sugar molecules in an *E. coli* cell (5,6). With a few exceptions (7,8), considered further below, the lipid A and Kdo domains of LPS (Figs. 1 and 2) are required for growth (5,9,10). In wild-type strains, additional core and O-antigen sugars are present (Fig. 1) (2,3). These complex glycoforms are not needed for growth but protect bacteria from antibiotics and complement-mediated lysis. The core and O-antigen domains are required for virulence, and consequently are present in most clinical and environmental isolates (3). The structures and biosynthesis of core and O-antigen sugars are reviewed elsewhere (2,3). Here, we focus on the biosynthesis of lipid A and its modification during transport to the outer membrane. The mechanisms of lipid A transport are covered in greater detail by Tommassen *et al.* in the 2007 issue of Annual Review of Microbiology.

2To whom correspondence should be addressed: raetz@biochem.duke.edu.

The innate immune response to lipid A

Most Gram-negative bacteria synthesize lipid A molecules resembling those made by *E. coli* (Fig. 2) (2,3). The lipid A moiety of LPS is detected by the TLR4/MD2 receptor of the mammalian innate immune system (11-17). Picomolar levels of lipid A induce macrophages to synthesize potent mediators of inflammation, like TNF-α and IL-1β (18,19). Lipid A furthermore activates the production of co-stimulatory molecules required for adaptive immunity (20,21). With mononuclear and endothelial cells, lipid A stimulates tissue factor production (22,23). All these events are desirable for clearing local infections. When overproduced systemically during sepsis, however, the inflammation caused by some of these proteins damages small blood vessels and can precipitate Gram-negative septic shock (24, 25). LPS, or even synthetic *E. coli* lipid A by itself, causes a similar pathology when injected into animals (26-28), supporting its proposed role in sepsis. The characteristic structural features of *E. coli* lipid A (Fig. 2), especially its two phosphate and acyloxyacyl groups, are needed to trigger full TLR4/MD2 activation in human cells (26). However, partial activation of TLR4/MD2 by certain lipid A substructures and analogues results in the production of an altered cytokine profile that retains the beneficial adjuvant effects of endotoxin but minimizes animal toxicity (29-31). Some lipid A analogues (usually containing fewer acyl chains) are potent TLR4/MD2 antagonists (16,32-35), with potential utility as human therapeutics (36). A crystal structure of TLR4/MD2 with a bound lipid A molecule or lipid A analogue is not yet available to clarify the mechanism of trans-membrane signaling (14). However, the crystal structure of the extra-cellular domain TLR3 (a TLR4 orthologue that is activated by double-stranded RNA) has recently been reported (37-39).

Discovery and overview of lipid A biosynthesis

The lipid A biosynthetic pathway may be viewed as having a conserved and a variable component. The conserved (constitutive) enzymes (Fig. 2) are intracellular, present in virtually all Gram-negative bacteria, and not generally subject to regulation (2,40). In contrast, the lipid A modification enzymes, discussed below, are mostly extra-cytoplasmic and vary from organism to organism. In many instances, the lipid A modification systems are induced or repressed by growth conditions, such as changes in pH, divalent cation concentrations or the presence of anti-microbial peptides (41-45). Most modification enzymes reside either on the periplasmic surface of the inner membrane or in the outer membrane (46-54). They are excellent markers for following the translocation of nascent LPS from its initial site of biosynthesis on the inner surface of the inner membrane to the outer surface of the outer membrane (55-60) (Fig. 1).

The systematic elucidation of the constitutive pathway for lipid A biosynthesis (Fig. 2) was enabled by the discovery of 2,3-diacylglucosamine 1-phosphate (lipid X) (61,62), a substance that had been overlooked in earlier work on *E. coli* lipids, because it is present at very low levels in wild-type cells (6,63). However, it accumulates as much as 500-fold, or to about 5-10 % of the total lipid, in certain kinds of phosphatidylglycerol-deficient mutants (61,62). The discovery of lipid X (61,62) coincided with the correct structure determination (64,65) and chemical synthesis of lipid A (66). Recognition of the existence of an acylated monosaccharide (62) representing a precursor to the proximal (right) subunit of lipid A (Fig. 2) greatly facilitated the development of testable hypotheses regarding the origin of lipid A from known lipids and carbohydrates present in *E. coli* (63,67,68).

THE CONSTITUTIVE ENZYMATIC PATHWAY OF LIPID A BIOSYNTHESIS

The nine enzymes of the constitutive lipid A pathway and the single-copy genes encoding them (Fig. 2) are conserved in Gram-negative bacteria like *E. coli* (2,69). The only exceptions are organisms like *Sphingomonas*, which make bioactive sphingolipids instead of lipid A (70).

The sequences of the lipid A genes are easily recognized when Gram-negative genomes are compared (71). LpxA, C and D are soluble proteins (72-74), whereas LpxB and LpxH are peripheral membrane proteins (75-77). LpxK, KdtA, LpxL and LpxM are integral inner membrane proteins (78-82). Their active sites are presumed to face the cytoplasmic surface of the inner membrane, given that their water-soluble co-substrates are cytoplasmic molecules (Fig. 2). Interestingly, higher plants like *Arabidopsis thaliana* encode significant orthologues of the constitutive enzymes within their nuclear genomes (2,83), but lipid A-like molecules have yet been identified in plants by mass spectrometry or NMR spectroscopy (84).

Fatty acylation of UDP-GlcNAc

The first step of lipid A biosynthesis, the fatty acylation of UDP-GlcNAc (Fig. 2) (67,85), is catalyzed by LpxA. *E. coli* LpxA requires the thioester *R*-3-hydroxymyristoyl acyl carrier protein (ACP) as its donor substrate (72,85). It does not recognize *R*-3-hydroxymyristoyl-coenzyme A. The active site of *E. coli* LpxA functions as a precise hydrocarbon ruler that incorporates C14 hydroxyacyl chains two orders of magnitude faster than C12 or C16 chains (86,87), consistent with the structure of *E. coli* lipid A (Fig. 2). In *Pseudomonas aeruginosa*, the LpxA ruler is reset to incorporate C10 chains (86,87), while in *Neisseria meningitidis* and *Leptospira interrogans* it measures C12 chains (88,89). Strains of *E. coli* in which *P. aeruginosa lpxA* replaces *E. coli lpxA* synthesize hybrid lipid A molecules in which C10 acyl chain are incorporated at positions 3 and 3′ (Fig. 2, *red* numbers). The rest of the lipid A molecule is unchanged (90). Single amino acid substitutions can switch *P. aeruginosa* LpxA to a C14- or *E. coli* LpxA to a C10-selective enzyme (87).

The crystal structure of LpxA (91-93) reveals that it is a homo-trimer (Fig. 3), constructed around multiple, contiguous hexad repeats. These motifs specify a unique secondary structure consisting of a left-handed helix of short parallel β-sheets. All hexad repeat-containing proteins studied to date are helical homo-trimers. Three hexads (18 amino acids) form one coil of the β-helix (91) (Fig. 3). The three identical active sites of LpxA, which were first proposed based on site-directed mutagenesis, are located at the subunit interfaces (93,94). A recent X-ray structure of *E. coli* LpxA with bound UDP-3-*O*-(*R*-3-hydroxydecanoyl)-GlcNAc (Fig. 3, *right* panel), a slow substrate in the reverse direction (94), has recently been solved at 1.8 Å (Williams and Raetz, in preparation). In addition to validating the proposed locations of the LpxA active sites (94), these studies provide a structural explanation for the extraordinary chain length selectivity of these enzymes.

An analogue of UDP-GlcNAc in which NH_2 replaces the GlcNAc 3-OH group

Many bacteria, including *L. interrogans* and *Acidithiobacillus ferroxidans*, contain a dehydrogenase (GnnA) and a transaminase (GnnB) that convert UDP-GlcNAc to the analogue UDP-GlcNAc3N, in which the GlcNAc 3-OH group is replaced with an amine (Fig. 4) (89, 95). LpxA of *L. interrogans*, which is absolutely selective for a C12 chain (89,95) (Fig. 4), acylates UDP-GlcNAc3N but not UDP-GlcNAc (89,95). This remarkable selectivity accounts for the fact that *L. interrogans* lipid A molecules contain four *N*-linked hydroxyacyl chains (96), as the rest of the pathway is conserved (not shown in Fig. 4). *E. coli* LpxA cannot discriminate between UDP-GlcNAc and UDP-GlcNAc3N (89,95), but the latter substrate is not available in *E. coli*. *A. ferroxidans* LpxA can utilize both UDP-GlcNAc and UDP-GlcNAc3N for lipid A biosynthesis, resulting in lipid A mixtures containing two, three of four *N*-linked acyl chains (89). A significant number of the Gram-negative bacteria sequenced to date contain GnnA and GnnB orthologues. The presence of additional *N*-linked acyl chains may increase the stability of lipid A to base hydrolysis or may prevent its degradation by lipases. A crystal structure of *L. interrogans* LpxA has recently been solved at 2.2 Å (Williams and Raetz, in preparation); this structural data should help elucidate the mechanism by which this enzyme differentiates sugar nucleotides.

Deacetylation of UDP-3-*O*-(acyl)-GlcNAc

The equilibrium constant (~0.01) for UDP-GlcNAc acylation by *E. coli* LpxA is unfavorable (72,94). Thus, the deacetylation of UDP-3-*O*-(acyl)-GlcNAc by LpxC is the actual committed step of lipid A biosynthesis (74,97). LpxC is a Zn^{2+}-dependent enzyme that is highly conserved in all Gram-negative bacteria (98,99). It displays no sequence similarity to other deacetylases or amidases. It is an excellent target for the development of novel antibiotics (10,100,101). Slow, tight-binding inhibitors of LpxC with low nM affinity have recently been reported (Fig. 5A). These compounds are *N*-aroyl-L-threonine hydroxamates (Fig. 5A). They possess antibiotic activity comparable to ciprofloxacin (102). The hydroxamate group presumably binds to the catalytic Zn^{2+} ion in a stereospecific manner. The recent X-ray (103-106) and NMR (107,108) structures (Fig. 6) of LpxC with the bound substrate-mimetic hydroxamate inhibitor TU-514 (Fig. 5B), the fatty acyl chain of which occupies a hydrophobic tunnel leading away from the LpxC active site (Fig. 6), may facilitate the design of inhibitors with even greater antibiotic activity. Clinical applications would include the treatment of cystic fibrosis patients infected with multi-drug resistant *P. aeruginosa*.

LpxC levels increase five- to ten-fold in cells treated with sub-lethal doses of LpxC inhibitors (109). Induction is not associated with increased transcription (109) but may be due to reduced LpxC turnover when lipid A biosynthesis is curtailed. LpxC induction is also seen in temperature-sensitive LpxA mutants in the absence of LpxC inhibitors (109). Although the signaling mechanisms controlling LpxC induction are unknown, two amino acids at the C-terminus of LpxC are critical for this regulation (110). The FtsH protease is partially responsible for regulating LpxC turnover in vivo (111) but additional processes cannot yet be excluded.

Following deacetylation, a second *R*-3-hydroxymyristate chain is added by LpxD to make UDP-2,3-diacyl-GlcN (Fig. 2) (73). The X-ray structure of LpxD (W. Hunter, personal communication) shows that it, like LpxA, is a homotrimer constructed around multiple contiguous hexad repeats.

Formation of the lipid A disaccharide

The pyrophosphate linkage of UDP-2,3-diacyl-GlcN is cleaved by LpxH, which catalyzes the attack of water on the α-phosphorus atom of the UDP moiety to form 2,3-diacyl-GlcN-1-phosphate (lipid X) (76,77) and UMP (Fig. 2). LpxH is unusual in that it is missing in about one third of the Gram-negative genomes. An alternative pyrophosphatase of this kind must exist in these strains, since all of them contain LpxD and LpxB (Fig. 2), but the relevant gene has not been identified. LpxH is a peripheral membrane protein that is stimulated *in vitro* by Mn^{2+}. This enzyme is distantly related to the phosphoprotein phosphatase family. Its structure is not yet available.

The β,1′-6 linked disaccharide that is characteristic of all lipid A molecules is generated by LpxB, which condenses UDP-2,3-diacyl-GlcN with lipid X (68,75) and releases UDP (Fig. 2). Like LpxH, LpxB is a peripheral membrane protein. It is a member of a unique family of glycosyltransferases, some of which are distantly related to MurG (112), as judged by PSI-BLAST analysis (113). LpxB is very useful for the chemo-enzymatic synthesis of lipid A analogues (114,115). Its crystal structure has not been reported. A second LpxB orthologue of unknown function is present in strains of *Legionella*, where it is required for growth inside of *Acanthamoeba* (116).

Kdo incorporation and secondary acylation

The integral inner membrane proteins LpxK (78,117), KdtA (WaaA) (118,119), LpxL (HtrB) and LpxM (MsbB) (79,80,82,120) catalyze the last four steps of the constitutive pathway in *E. coli* (Fig. 2). Each protein contains one predicted membrane-spanning segment at its *N*-

terminus. The active sites likely face the cytoplasm. LpxK phosphorylates the 4′-position of the disaccharide 1-phosphate generated by LpxB (Fig. 2) to form lipid IV_A (121). This important precursor is an excellent endotoxin antagonist in human cells, but an agonist of reduced potency in the mouse (33). This unusual pharmacology is determined by the source of the TLR4/MD2 complex (14,122-124). Hexa-acylated lipid A dimerizes human TLR4/MD2, whereas lipid IV_A does not (14,122-124).

Next, two Kdo residues are incorporated by the bifunctional enzyme KdtA (WaaA) (118, 119,125). The labile sugar nucleotide CMP-Kdo is the Kdo donor (40,126,127). The second Kdo unit is incorporated much more rapidly than the first, and therefore the intermediate with a single Kdo residue does not accumulate (Fig. 2). However, in *Hemophilus influenzae, Vibrio cholerae, Bordetella pertussis*, and several other organisms, KdtA incorporates only one Kdo residue (128). A special kinase (KdkA), unique to these bacteria (128,129), then incorporates a phosphate group at the same position where the outer Kdo residue is added by *E. coli* KdtA (Fig. 2). *Hemophilus kdtA* and *kdkA* in combination can rescue a heptose-deficient *E. coli* mutant with a deletion in its own *kdtA* gene (130). When the heptose region of the core is intact, however, a monofunctional Kdo transferase can rescue a KdtA deletion mutant (131). KdtA of *Chlamydia trachomatis* incorporates at least three Kdo residues and can also functionally substitute for *E. coli* KdtA (9,132).

The last steps of *E. coli* lipid A biosynthesis involve the addition of the secondary lauroyl and myristoyl residues to the distal glucosamine unit (Fig. 2) (120) by LpxL and LpxM, which require the Kdo disaccharide moiety in their substrates for activity (82,120). LpxL and LpxM prefer acyl-ACP donors but can also function with acyl-coenzyme A substrates (Six and Raetz, in preparation). LpxL and LpxM display significant sequence similarity to each other (79, 80), but not to LpxA or LpxD. LpxL and LpxM are distantly related to the lysophosphatidic acid acyltransferase family (Six and Raetz, in preparation). The *lpxM* gene is not required for growth in *E. coli* (82,133). *S. typhimurium* and *Shigella lpxM* mutants are attenuated in their ability to cause inflammation (134-136). Both *lpxL* and *lpxM* can be deleted, provided the cells are grown on minimal medium or at low temperature (82). Tetra-acylated lipid A, which accumulates in *lpxL* mutants, is not rapidly transported from its site of biosynthesis on the inner surface of the inner membrane to the outer membrane (82).

The *E. coli* chromosome encodes an additional gene homologous to *lpxL*, termed *lpxP*, which is expressed at low temperature (12 °C) (81,137). LpxP incorporates palmitoleate in place of laurate (not shown in Fig. 2), perhaps reflecting the need to adjust outer membrane fluidity (81,137). In *Yersinia pestis, lpxL* is missing but *lpxM* and *lpxP* are present (138). Consequently, *Y. pestis* synthesizes tetra-acylated lipid A at 37 °C but makes hexa-acylated lipid A at 25 °C (138). As noted above, tetra-acylated lipid A is a relatively weak TLR4/MD2 agonist in the mouse and an antagonist in humans (138). Introduction of the *E. coli lpxL* gene into *Y. pestis* permits the synthesis of hexa-acylated lipid A (a potent TLR4/MD2 agonist) at all temperatures (138). Such constructs are fully attenuated in a mouse infection model and provide immunity against a subsequent challenge with wild-type *Y. pestis* (138).

Why lipid A is essential for growth in most Gram-negative bacteria remains uncertain. It may be required for the proper folding of some outer membrane proteins (139,140). Recently, Nishiyama *et al.* have reported a lipid A-like factor required for signal recognition particle/SecYEG-dependent and -independent membrane protein integration in *E. coli* (141). Because mass spectrometry and NMR spectroscopy were not used for structural analysis, the chemical nature of this factor and its identification as lipid A-related remains in question (141).

N. meningitidis is unusual in that its *lpxA* gene can be inactivated (142); such mutants grow slowly without lipid A but nevertheless can assemble a functional outer membrane, albeit missing some lipoproteins (7).

EXPORT OF NEWLY SYNTHESIZED LPS AND PHOSPHOLIPIDS

How *E. coli* lipids cross the inner membrane and are transported to the outer membrane (Fig. 7) is not fully understood (55,143). A clue to bacterial lipid transport emerged from studies of *lpxL* mutants (Fig. 2) and their suppression by multiple copies of *msbA* (144-146). LpxL is the lauroyl transferase of lipid A biosynthesis (Fig. 2) (79). LPS with tetra-acylated lipid A accumulates in inner membranes of *lpxL* mutants at 42°C, and growth on broth is inhibited (146). MsbA is an essential ABC transporter (Fig. 7), closely related to eucaryotic Mdr proteins (144). MsbA over-expression restores the growth of *lpxL* mutants at 42°C without restoring laurate addition, resulting in export of LPS with tetra-acylated lipid A to the outer membrane (146). *E. coli msbA* knockouts are not viable (144), but their analysis is complicated by two factors. First, long times (4-8 h) are needed to dilute out pre-existing MsbA supplied in *trans* from a temperature-sensitive plasmid (146). Second, the *lpxK* gene (Fig. 2), which is immediately downstream in an operon with *msbA*, is also essential for growth (117,146).

To gain a clearer understanding of MsbA function, a temperature-sensitive point mutant of *E. coli* (WD2) was isolated in which there is a single A270T substitution in the fifth predicted membrane-spanning segment (143), located near the proposed MsbA dimer interface on the periplasmic side of the inner membrane (147-149). This mutant protein is rapidly inactivated at 44 °C. Export of all major lipids (both LPS and phospholipids) to the outer membrane is inhibited by ~90 % in WD2 after 30 minutes at 44 °C (143), as judged by pulse-labeling studies. Lipid A biosynthesis, phospholipid biosynthesis and export of major outer membrane proteins are not immediately affected (143). However, minor protein species have not been examined (143). The cells do not undergo rapid lysis, suggesting that peptidoglycan assembly is not inhibited (143). Electron microscopy reveals inner membrane invaginations in WD2 at 44°C, consistent with increased surface area secondary to a selective block of lipid export (143). However, the covalent modifications of newly-synthesized lipid A with 4-amino-4-deoxy-L-arabinose (L-Ara4N) or phosphoethanolamine moieties (Fig. 8), which occur on the outer surface of the inner membrane, are inhibited at 44 °C in temperature-sensitive MsbA mutants (55), consistent with the idea that MsbA is the flippase for LPS (Fig. 8).

Several recent X-ray structures of the homodimeric MsbA protein at 4.2-4.5 Å (147-149) support the proposed flippase function of MsbA (143) and suggest the existence of multiple conformational states. However, the relatively low resolution of these structures (147-149), compared with those of other ABC transporters, has hampered structural interpretation and raised serious issues regarding the published conformations of the MsbA protein (150,151). An improved, high-resolution structure of MsbA, preferably with a well-defined, ligand such as Kdo_2-lipid A (152), would greatly facilitate further mechanistic studies of MsbA.

Studies of MsbA-mediated LPS flip-flop in *E. coli* membrane vesicles or in purified, reconstituted systems have not been reported. Why phospholipid transport to the outer membrane is blocked in *msbA* mutants is also unclear (143). There is evidence that phospholipid flip-flop is not ATP-dependent in bacterial inner membrane vesicles (153). Although purified MsbA is a lipid-activated ATPase (154), phospholipid flip-flop could not be demonstrated in liposomes containing MsbA alone (155). MsbA may indeed be a specific flippase primarily for LPS, or inhibition of phospholipid export in *msbA* mutants (143) might be secondary to LPS accumulation. Alternatively, other proteins may be needed together with MsbA to catalyze phospholipid and LPS flip-flop. In some marine bacteria, MsbA is fused via its *C*-terminus to LpxK (156).

Recently, *msbA* has been identified as a multi-copy suppressor of Kdo-deficient mutants of *E. coli* (8), including strains with deletions in the Kdo transferase (Fig. 2) (9) (Reynolds and Raetz, in preparation). Additional uncharacterized suppressor mutations and multi-copy suppressors have also been reported (8); their analysis should provide exciting new insights into lipid A trafficking and function. In Kdo-deficient strains harboring the appropriate suppressor, lipid IV$_A$ is sufficient for outer membrane biogenesis and cell viability (8), but the cells are still sensitive to the LpxC inhibitor CHIR-090 (Reynolds and Raetz, in preparation). The outer membrane protein profile of Kdo-deficient strains is remarkably similar to that observed with wild-type *E. coli* (8). It appears that MsbA over-production can overcome the transport defect associated with both under-acylated (146) and Kdo-deficient (157) LPS precursors.

In *N. meningitidis* slow growth is possible without LPS (142). Consequently, one can delete the *msbA* gene in *N. meningitidis* and retain the ability to assemble an outer membrane (158), yet *N. meningitidis msbA* can partially complement the temperature-sensitive *E. coli msbA* mutant WD2 (158). It may be that *E. coli* MsbA is required for the rapid flipping of phospholipids, given the fast growth of *E. coli* versus *N. meningitidis*.

Additional proteins are required to assemble and attach O-antigen (2-4), and to shuttle nascent LPS across the periplasm and into the outer membrane (Fig. 7). The essential periplasmic protein YhbN(LptA) has recently been implicated in this process (159). A linked cytoplasmic ABC transporter subunit homologue, designated LptB, also plays a role (159), perhaps in conjunction with the additional trans-membrane protein YbrK (159). The LptA/B transporter complex is thought to function after MsbA catalyzed LPS flipping, possibly extracting nascent LPS from the periplasmic surface of the inner membrane on its way to the outer membrane (159). Next, the outer membrane protein Imp (56,160) and its lipoprotein partner RlpB (60) are thought to flip nascent LPS within the outer membrane, bringing it to the exterior. Depletion of LptA/B (159) or Imp/RlpB (56,160) causes the accumulation of aberrant, heavy membranes, apparently located within the periplasm. As with MsbA, in vitro transport assays with pure proteins have yet to be developed to validate these proposals.

Although eucaryotic Mdr proteins are thought to catalyze phospholipid flip-flop in vitro, mouse mutants lacking the three major Mdr proteins are viable and show no generalized defects in lipid trafficking (161,162). Given the multitude of Mdr-like proteins in mammalian genomes, functional redundancy may account for the lack of phenotype. However, mouse Mdr2 knockouts display a specific lipid transport deficiency in that they cannot pump phosphatidylcholine into their bile (163). Many of the additional Mdr-like proteins present in animal cells have recently been implicated in the transport of specific lipids (164). As with MsbA, however, simple and direct *in vitro* assays for Mdr catalyzed lipid flip-flop are not well developed.

LIPID A MODIFICATION SYSTEMS IN GRAM-NEGATIVE BACTERIA

Overview of *E. coli* and *Salmonella* lipid A modification enzymes

E. coli K-12 and *S. typhimurium* contain enzymes for modifying lipid A with phosphoethanolamine (Fig 8, *red*) (50, 52, 53, 165), L-Ara4N (Fig. 8, *green*) (41, 47, 48, 165, 166) and/or palmitate (46, 167, 168) (Fig. 8, *black*). Two selective deacylases and a dioxygenase are additionally present in *S. typhimurium* (Fig. 8). Many of these enzymes are regulated in response to changes in growth conditions. For instance, the attachment of phosphoethanolamine by the enzyme EptA (50) and L-Ara4N by the enzyme ArnT (Fig. 8) (47) is induced by activation of the PmrA transcription factor, either by exposure of cells to mild acid or by *pmrA* constitutive mutations (44, 169, 170). The L-Ara4N group is positively charged at pH 7. It neutralizes the negative charge of the lipid A 4′-phosphate group (Fig. 8),

thereby reducing bacterial susceptibility to cationic anti-microbial peptides and polymyxin (41, 169-171).

Addition of polar groups to *E. coli* and *Salmonella* lipid A

The biosynthesis of L-Ara4N and the mechanism of its attachment to lipid A have recently been elucidated. The process starts with the oxidative decarboxylation of UDP-glucuronic acid by the *C*-terminal domain of ArnA (Fig. 9) (172). The resulting UDP-4-ketopentose is transaminated by ArnB (173) to generate UDP-L-Ara4N, which is then formylated by the *N*-terminal domain of ArnA (174). X-ray structures of ArnA (175,176) and ArnB (177) are available, as both are soluble proteins. How they interact and transfer their products between their active sites is unknown. Only the *N*-formyl derivative of UDP-L-Ara4N (Fig. 9, *magenta modification*) can be transferred to undecaprenyl phosphate by ArnC (174). The subsequent deformylation by ArnD to generate undecaprenyl phosphate L-Ara4N (Figs. 9 and 10) renders the pathway irreversible (174). After transport of undecaprenyl phosphate-L-Ara4N to the outer surface of the inner membrane, ArnT transfers the L-Ara4N residue to the 4′-phosphate group of lipid A (Fig. 9) (47). A possible inner membrane transport system for undecaprenyl phosphate-L-Ara4N, encoded by the *arnE* and *arnF* genes (Fig. 9), has recently been identified (Yan and Raetz, in preparation).

Phosphoethanolamine transfer to lipid A by the enzyme EptA (Fig. 8), predominantly to the 1 phosphate group, likewise occurs on the outer surface of the inner membrane (50,52,55). Under certain growth conditions or in the absence of L-Ara4N, EptA can modify the lipid A 4′ position with a second phosphoethanolamine moiety (not shown in Fig. 8) (44). Phosphatidylethanolamine serves as the phosphoethanolamine donor substrate. In contrast to the L-Ara4N group, which is critical for polymyxin resistance (41,174,178), the roles of the phosphoethanolamine modifications remain uncertain.

E. coli and *S. typhimurium* both contain a related enzyme, designated EptB, which is homologous to EptA but is not regulated by PmrA. Instead, EptB is induced by the addition of 5 mM Ca^{2+} to the growth medium (53,179) and is under the control of the σ^E transcription factor (180). EptB transfers a phosphoethanolamine moiety from phosphatidylethanolamine to the outer Kdo residue (Fig. 8). Diacylglycerol is generated as the byproduct (53). Heptose-deficient mutants lacking EptB are killed by the presence of 5 mM Ca^{2+} in the growth medium (53), suggesting a function in the maintenance of outer membrane stability.

Additional Ept enzymes are likely necessary to control the incorporation of phosphoethanolamine into other cell envelope components including the first inner core heptose sugar, which is modified in a PmrA-dependent manner by an *ept* gene homologue in *S. typhimurium* (181). Phosphoethanolamine is not normally incorporated into the lipid A of *E. coli* K-12 until the cells are exposed to mildly acidic growth conditions (44), but pathogenic *E. coli* O157:H7 expresses this modification constitutively (182). The latter organism harbors an *ept* gene homologue in the plasmid pO157-encoded *shf* locus (183,184), but the corresponding gene is replaced by *virK*, an unrelated gene needed for intercellular spreading in *Shigella flexneri* (136). The plasmid-borne *shf* loci of *E. coli* O157:H7 and *S. flexneri* also encode a second *lpxM* gene homologue, which must be inactivated together with the chromosomal copy in order to achieve virulence attenuation (136,183). The *shf* loci also encode the *wabB* glycosyltransferase gene that controls attachment onto the third heptose sugar of GlcNAc, which is a unique feature of the R3 inner core (184).

When grown in the presence of 10 mM Mg^{2+} at neutral pH, *E. coli* and *S. typhimurium* synthesize a subset of lipid A molecules (20-30 %) in which a diphosphate group is present at the 1-position of lipid A (not shown in Figs. 2 or 8) (166). The diphosphate residue is generated on the periplasmic surface of the inner membrane by YeiU, an undecaprenyl diphosphate-

specific phosphotransferase (185) (Trent *et al.*, preparation). YeiU also functions as an undecaprenyl diphosphate phosphatase. Undecaprenyl diphosphate is generated on the outer surface of the inner membrane during the polymerization of peptidoglycan (Fig. 1) (186). The lipid A diphosphate groups, synthesized by YeiU and EptA, might function to stabilize and/or balance the surface electrostatics of the outer membrane depending on environmental conditions. However, YeiU is not essential for cell growth on nutrient broth.

Modification of the fatty acyl chains of *E. coli* and *Salmonella* lipid A

Modification of lipid A with palmitate by PagP (CrcA) (Fig. 8) is under control of the PhoP/PhoQ system, which is activated by low Mg^{2+} concentrations or cationic anti-microbial peptides (42,44,168). An acidic patch on the surface of the periplasmic domain of the PhoQ sensor-kinase is proposed to orient parallel to the membrane plane, which allows Mg^{2+} to bridge the acidic patch with anionic phospholipid polar head groups and maintain a repressed regulatory state (45,187). The PhoP/PhoQ system is thought to be activated either by growing cells under Mg^{2+}-limited conditions or, under Mg^{2+}-replete conditions found during growth within macrophage phagosomal vacuoles (188), upon displacement of Mg^{2+} by cationic anti-microbial peptides (45). In *S. typhimurium*, PhoP/PhoQ activation triggers the PmrA/PmrB pathway via a post-translational mechanism using an effector known as PmrD, but the *pmrD* gene is non-functional in *E. coli* (189). Consequently, PmrA/PmrB-dependent modification of the lipid A phosphate groups can be uncoupled from the PhoP/PhoQ-dependent incorporation of palmitate only in *E. coli* (57).

S. typhimurium mutants unable to add palmitate to lipid A are sensitive to certain cationic anti-microbial peptides including representatives of amphipathic α-helical (C18G) and β-sheet (protegrin) structural classes, but not including polymyxin (168). Although the amphipathic α-helical peptides LL37 and C18G are both inducers of the PhoP/PhoQ system (45), PagP only provides measurable resistance to the latter (190). PagP is required for animal infections caused by *Legionella pneumophila* and *Bordetella bronchiseptica*, where it provides resistance to cationic anti-microbial peptides and antibody-mediated complement lysis, respectively (191-193). The *pagP* gene is distributed among a narrow group of primarily pathogenic bacteria, and its regulation often correlates with their pathogenic lifestyle (194). For example, the Bvg virulence regulator controls *B. bronchiseptica* PagP expression (166) and the incorporation of palmitate into *Y. pseudotuberculosis* lipid A predominates at the body temperature of the infected host (195).

Palmitate transfer to lipid A occurs on the outer surface of the outer membrane where PagP uses phospholipids as palmitoyl donors (46). Both X-ray and NMR structures of *E. coli* (Fig. 11) have been reported (196,197). The active site of PagP faces the exterior (197), suggesting that its activity is regulated by phospholipid access, as phospholipids are not always present on the outer surface of the outer membrane. PagP is an 8-stranded anti-parallel β-barrel, preceded by an *N*-terminal amphipathic α-helix (Fig. 11). The β-barrel axis is tilted by ~25 degrees with respect to the membrane plane (196,198). Like most β-barrel outer membrane proteins, the interior of the inner leaflet-exposed half of the molecule is largely polar, but the interior of the outer LPS-exposed half is decidedly hydrophobic and lined by a bound molecule of the detergent lauroyldimethylamine-*N*-oxide (Fig. 11). Proline residues punctuate the β-strands at two opposing sites and disrupt the continuity of β-barrel hydrogen bonding around the bound detergent, thus providing obvious routes for lateral access of lipid substrates from within the outer leaflet of the membrane.

The mechanism by which PagP selects palmitate in preference to other fatty acyl chains involves another "hydrocarbon ruler", which can be reset to recognize shorter fatty acids by means of single amino acid substitutions (196). Substitution of Gly88 lining the floor of the lauroyldimethylamine-*N*-oxide binding pocket can make the pocket more shallow by the same

length as the introduced side-chain, and this affords a corresponding shortening of the acyl-chain that is selected by the enzyme (196). The aromatic side-chains of Tyr26 and Trp66 undergo a rare exciton interaction, which can be detected by circular dichroism spectroscopy and provides a sensitive probe to gauge methylene unit resolution of acyl-chain selection (Khan *et al.*, in preparation). The ability to modulate PagP acyl-chain selection might be important for the preparation of endotoxin antagonists and adjuvants (30,31,199).

The amino acid residues implicated in catalysis Asp76, His33, and Ser77 are not organized into a catalytic triad characteristic of serine esterases (196,197), but PagP can exist in a conformational equilibrium between two dynamically distinct states (200). Although the known structure represents an inhibited R-state, an ordering of residues in and around the disordered cell-surface loop that connects the first two β-strands is thought to be necessary to afford a catalytically-competent T-state, the structural details of which remain to be elucidated. Knowledge of the T-state structure would likely reveal details of the PagP catalytic mechanism.

PagP can function as a membrane-intrinsic probe to monitor either the transport of LPS to the outer membrane (158) or the translocation of phospholipids into the outer leaflet, which occurs when LPS organization is disrupted by mutations that affect the presentation of LPS on the cell surface (60), or by EDTA that chelates Mg^{2+} needed to neutralize negative charge repulsions between neighboring LPS molecules (57). Phospholipid accumulation in the outer leaflet can render cells sensitive to hydrophobic antibiotics and detergents that are normally impermeable when lipid asymmetry is maintained. An outer membrane permeability defect observed in an LpxM-deficient mutant of *E. coli* O157:H7 was recently associated with PagP activation through a lipid perturbation mechanism, which revealed that PagP can contribute to the restoration of the permeability barrier (Kim *et al.*, in preparation). Interestingly, PagP activation in this mutant also induced a truncation of the R3 core at the level of the first outer core glucose unit, which could be rescued by restoring the cytosolic pool of UDP-glucose. The implication that PagP activation in the outer membrane can control cytoplasmic functions is consistent with observations that LPS modifications, including palmitoylation of lipid A, can initiate signal transduction across the bacterial cell envelope to the transcription factor σ^E (201).

S. typhimurium contains several additional lipid A modification enzymes that are not present in wild-type *E. coli* K-12. PagL is an outer membrane lipase that is regulated by PhoP/PhoQ and removes the *R*-3-hydroxymyristoyl chain at position 3 of lipid A (Fig. 8) (49). LpxR, a distinct outer membrane lipase, cleaves the intact 3′-acyloxyacyl moiety of Kdo_2-lipid A (Fig. 8) (54). *In vitro* studies have shown that LpxR activity is Ca^{2+}-dependent and Kdo-activated (54). Finally, LpxO is an inner membrane enzyme that hydroxylates the 3′ secondary acyl chain of Kdo_2-lipid A in the presence of O_2 (Fig. 8), using Fe^{2+} and α-ketoglutarate as cofactors (202,203). LpxO is not under the control of PhoP/PhoQ, and its active site faces the cytoplasm (44,55). The crystal structures of LpxO and LpxR have not yet been determined.

Expression of LpxO, LpxR or PagL in *E. coli* K-12 leads to the expected lipid A modifications (Fig. 8) (49,54,202). Interestingly, PagL and LpxR are latent in *S. typhimurium*, unless over-expressed (49,54), suggesting the presence of endogenous inhibitors such as the L-Ara4N moiety (204). The functions of these enzymes are unknown, but PagL and LpxR would likely attenuate the cytokine inducing ability of LPS (205-207).

Despite its absence from *E. coli*, PagL homologues are more widely distributed than PagP, although PagL is not primarily restricted to pathogenic organisms (208). The crystal structure of PagL from *P. aeruginosa* reveals an overall fold that is similar to PagP (209), and its active site likewise faces the outer surface of the outer membrane (Fig. 11). Both molecules are 8-stranded anti-parallel β-barrels and are strikingly tilted in the outer membrane. However, PagL

differs in the presentation of its lipid substrate to a distinct catalytic triad formed by Glu140, His126, and Ser128 on the β-barrel exterior. Energy minimization of the model substrate lipid X reveals that acyl-chains likely bind into hydrophobic grooves on the β-barrel exterior (209). Although the enzyme normally encounters *R*-3-hydroxydecanoyl chains in its substrates *in vivo*, it also utilizes *R*-3-hydroxymyristoyl chains *in vitro*, which indicates that acyl-chains encountered on the β-barrel exterior cannot be measured with the same precision as performed by PagP. The potential of PagL to dimerize at an interface between active sites suggests a potential mechanism to inhibit activity in the outer membrane (209).

Modification of *Francisella* and *Helicobacter* lipid A

Francisella tularensis is the cause of tularemia, a highly contagious pulmonary disease of humans and animals (210). *Francisella novicida* U112, a related environmental organism, does not infect humans, and affords a practical model system for laboratory investigation (211). Strains of *Francisella* synthesize relatively little LPS, but do contain significant amounts of free lipid A, which can be extracted with chloroform-methanol together with the glycerophospholipids (212). The biological significance of free lipid A, which lacks Kdo and other core sugars, is unclear (212). The genomes of *Francisella* encode all the enzymes of the constitutive lipid A biosynthetic pathway, including the Kdo transferase and enzymes for core sugar addition (213). It may be that nascent lipid A is pumped out of the cell by MsbA more rapidly than it is glycosylated by KdtA. Alternatively, free lipid A may arise from nascent LPS by the action of an unusual Kdo hydrolase present in *Francisella* membranes (58). However, a Kdo hydrolase is also present in membranes of *Helicobacter pylori* (214), but free lipid A is not abundant. The gene encoding the Kdo hydrolase has not yet been identified.

The predominant lipid A species present in *Francisella* are shown in Fig. 12 (upper *right*). Interesting features (also seen with the portion of the lipid A that is linked to *Francisella* LPS) include the absence of the 4′-phosphate group and the 3′ acyl chain (212,215). A galactosamine residue, which is a cationic sugar resembling L-Ara4N, is attached to the 1-phosphate group of *Francisella* lipid A (212,215). Under some conditions, the 1-phosphate and galactosamine groups appear to be missing (Fig. 12, lower right structure) (216).

Some of the novel enzymatic reactions that account for these interesting lipid A modifications have been identified (Fig. 12). The lipid A phosphate groups are removed by two distinct inner membrane phosphatases, designated LpxE and LpxF (Fig. 12), the active sites of which face the periplasmic surface of the inner membrane (58,59). Expression of LpxE in strains of *E. coli* or *Salmonella* leads to nearly quantitative dephosphorylation at the 1-position (58). Expression of LpxF in wild-type *E. coli* has no effect, because LpxF does not dephosphorylate lipid A species containing a secondary acyl chain at the 3′-position (59). However, LpxF expression leads to complete loss of the 4′-phosphate moiety in *lpxM* mutants of *E. coli* or *Salmonella*, which synthesize mainly penta-acylated lipid A species (Fig. 2) (59). Cells of *Salmonella* expressing *lpxE* synthesize the non-toxic, adjuvant form of lipid A (also known as monophospho-lipid A or MPLA) (30,31), which is usually prepared by mild acid hydrolysis of LPS or by chemical synthesis. LpxE-expressing strains may be useful as live oral vaccines, assuming that the excessive inflammation that is normally caused by *Salmonella* lipid A is indeed suppressed.

Disruption of the *lpxF* gene in *F. novicida* (Fig. 12) results in the quantitative retention of the lipid A 4′ phosphate group with the accumulation of the species shown at the top center of Fig. 12 (217). When the 4′-phosphate moiety is left in place, the 3′ acyl chain is not removed (217), suggesting an obligatory order of processing. Because there is no *lpxR* gene in *Francisella* (213), it is unclear how the 3′-acyl chain is actually removed. *H. pylori* lipid A, like that of *F. novicida*, lacks both the 4′-phosphate group and the 3′-acyl chain(s). There is no *lpxF* gene in *H. pylori* (218), but an orthologue of *lpxR* is present. When *lpxR* is inactivated in

H. pylori, a hexa-acylated lipid A species lacking the 4′-phosphate group accumulates (Trent *et al.* in preparation), suggesting that *H. pylori* contains a distinct 4′-phosphatase that can dephosphorylate lipid A molecules containing a secondary 3′-acyl chain.

The mutant of *F. novicida* lacking *lpxF* is hypersensitive to cationic antimicrobial peptides and is avirulent in a mouse infection model (217). Following short-term intraperitoneal injection, the *lpxF* mutant bacteria trigger the production of a subset of cytokines, suggestive of TLR2 activation, whereas wild-type cells do not (217). Unlike the *Y. pestis* construct described above (138), the lipid A of *Francisella lpxF* mutant bacteria does not activate TLR4 (217), and *lpxF* mutant cells do not trigger the production of TNFα (217). Instead, the hypersensitivity of the *lpxF* mutant to cationic anti-microbial peptides (217) may cause damage to the bacterial envelope and expose other ligands, such as membrane lipoproteins for TLR2 or bacterial DNA for TLR9 (17). The potential of *lpxF* mutants as novel vaccines for the prevention of tularemia has not yet been explored.

Deletion of the single *arnT* gene homologue present in *F. novicida* leads to the production of lipid A molecules lacking the galactosamine modification (212), consistent with the finding that undecaprenyl phosphate-galactosamine (Fig. 12) is present amongst the minor lipids of *F. novicida* (Wang and Raetz, in preparation). The galactosamine modification pathway in *Francisella* therefore appears to be analogous to the L-Ara4N pathway (Fig. 9) in *E. coli*. Interestingly, the live vaccine strain of *F. tularensis*, like the *arnT* mutant of *F. novicida*, lacks the galactosamine modification on its free lipid A (212). Whether this feature is due to the absence of ArnT in the live vaccine strain or the inability to synthesize the undecaprenyl phosphate-galactosamine donor substrate (Fig. 12) is unclear.

Lipid A processing in *Rhizobium leguminosarum* and *Rhizobium etli*

The plant endosymbionts *R. leguminosarum* and *R. etli* synthesize a complex mixture of lipid A molecules that lack the 1- and 4′-phosphate groups found in most other Gram-negative bacteria (Fig. 13) (219-221). In a subset of molecular species, the anomeric carbon atom of the proximal unit is oxidized to a carboxylic acid (Fig. 13) (219-221). Galacturonic acid residues are attached to the outer Kdo moiety (not shown) and to the 4′-position of lipid A (219-221). Both organisms synthesize mainly penta-acylated lipid A molecules (220,221) with an unusually long secondary acyl chain at the 2′-position (Fig. 13) (220,221); this is a characteristic structural feature of the lipid A from many Rhizobiaciae (222). A portion of the lipid A molecules are deacylated at position 3 (223), and there is considerable fatty acid chain length heterogeneity (Fig. 13), when contrasted with *E. coli* lipid A (152,220,221). The core sugars beyond the Kdo region of *Rhizobium* LPS are also very different from those of *E. coli* (224, 225) in that the heptose units are replaced by mannose, galactose and Kdo (not shown in Fig. 13).

The enzymology, genetics and topography of *R. leguminosarum* and *R. etli* lipid A biosynthesis have been investigated in considerable detail. These bacteria contain orthologues of the first seven *lpx* genes found in *E. coli* (Fig. 2) (226), and therefore they initially synthesize the tetra-acylated precursor Kdo_2-lipid IV_A, shown in Figs. 13 and 14. The diverse lipid A molecular species of *Rhizobium* (Fig. 13) are generated from Kdo_2-lipid IV_A by enzymes that are not present in *E. coli*. For instance, the long secondary acyl chain is incorporated by LpxXL, a distant orthologue of LpxL (227), requiring a special acyl carrier protein termed ACP-XL (Fig. 14) (228). *R. leguminosarum* and *R. etli* also contain the phosphatases LpxE (58,229) and LpxF (59), which catalyze the removal of the 1- and 4′-phosphate groups respectively (Fig. 14), as in *Francisella*. Following removal of the 1-phosphate moiety, LpxQ (230,231) can oxidize the proximal glucosamine of *Rhizobium* lipid A in the presence of O_2 to form an aminogluconate unit. Removal of the 4′-phosphate group by LpxF is necessary for the incorporation of the 4′-galacturonic acid moiety (Fig. 14), which appears to involve a polyisoprene phosphate sugar

donor (rather than a sugar nucleotide) (Ingram and Raetz, unpublished). Similarly, the incorporation of galacturonate into the Kdo region of *Rhizobium* LPS by the enzymes RgtA and RgtB (Fig. 14) requires dodecaprenyl phosphate galacturonic acid as the donor substrate (232,233). RgtA and RgtB (Fig. 14) are distantly related in sequence and membrane topography to ArnT (232) (Fig. 9).

The precise order of Kdo_2-lipid IV_A modification in *Rhizobium* (Fig. 14) is not fully established. In vitro, there is no obligatory order of enzymatic processing, with the exception of LpxE preceding LpxQ, and LpxF preceding RgtD (Fig. 14). However, several lines of evidence strongly support the enzymatic topography shown in Fig. 15, in which LpxE, LpxF, and the Rgt enzymes function on the outer surface of the inner membrane, and LpxQ and PagL act in the outer membrane. Heterologous expression of the inner membrane phosphatases LpxE or LpxF in the appropriate strains of *E. coli* results in nearly complete and selective lipid A dephosphorylation, provided that the LPS flippase MsbA (Figs. 7 and 15) is functional (58, 59). The involvement of a dodecaprenyl phosphate-linked galacturonic acid donor, instead of a sugar nucleotide, is likewise consistent with galacturonate addition to lipid A occurring on the outer surface of the inner membrane (Fig. 15) (232,233), analogous to L-Ara4N in polymyxin-resistant *E. coli* (Figs. 8 and 9) (48). PagL and LpxQ are recovered in the outer membrane when expressed in *E. coli* (49,230,231). LpxQ efficiently generates lipid A containing aminogluconate when co-expressed with LpxE in *E. coli* (Ingram and Raetz, unpublished).

The biological significance of the lipid A modification systems of *Rhizobium* has been evaluated by genetics. In each instance studied to date, the relevant enzymes were first identified by the development of in vitro biochemical assays, followed by the expression cloning of the corresponding structural genes (59,225,227-229,231,232). Subsequent deletion of these structural genes caused the accumulation of the predicted, structurally altered lipid A species, demonstrating the biological relevance of the enzymatic approach. For instance, deletion of *lpxXL* or *acpXL* results in the failure to incorporate the long secondary acyl chain (Fig. 13) (234,235). These mutant bacteria grow slowly, and they are hypersensitive to detergents and low pH (234,235). However, these mutants are nevertheless able to form partially functional nodules in their host plants. Deletion of *Rhizobium* LpxE or LpxF results in the retention of the 1- or 4′-phosphate moieties, respectively (Sohlenkamp, Ingram and Raetz, unpublished). In the *lpxE* mutant, the aminogluconate cannot be generated, whereas in the *lpxF* mutant the 4′-galacturonate residue is not incorporated. Studies of the phenotypes of the mutants should provide insights into the functions of these structural features.

Unusual lipid A modifications in other bacteria

Given the diversity of gram-negative bacteria, it is likely that many additional lipid A modification enzymes exist. Some of modification enzymes are present in only a few types of organisms. For instance, *L. interrogans* contains a lipid A methyl transferase (LmtA) that uses *S*-adenosylmethionine to methylate the 1-phosphate group (236). LmtA is distantly related to eucaryotic methyl transferases involved in the *C*-terminal processing of farnesylated proteins (236). LmtA can be expressed in *E. coli* resulting in methylation of about half the lipid A (236). The function of lipid A methylation is unknown.

Some strains of *Acinetobacter* make LPS containing an analogue of Kdo, known as Ko, in which the CH_2 moiety at the Kdo 3-position is hydroxylated (237). Interestingly, the KdtA orthologue of this organism utilizes CMP-Kdo in vitro (238), raising the possibility Ko is formed after the addition of Kdo to lipid IV_A. A Kdo-selective dioxygenase, analogous to LpxO (Fig. 8), might account for these observations. The relevant gene has not yet been identified.

FUTURE DIRECTIONS FOR LIPID A AND LPS RESERACH

The following questions and research directions will dominate lipid A research in the coming years.

1) Why is lipid A essential for growth in most gram-negative bacteria?

Careful genetic and biochemical examination of unusual systems like *N. meningitidis*, in which lipid A is not required for growth (142), might prove informative. The powerful approach of searching for second-site suppressor mutations in *E. coli* has recently provided new insights into the role of the Kdo disaccharide (8) but has not been applied systematically to all the genes of the constitutive pathway.

2) What is the relevance of the *lpx* gene orthologues present in higher plants?

Mutants of *Arabidopsis* lacking *lpxA* are viable but lack fine root hairs (Liu, Nikolau and Raetz, in preparation). However, despite suggestive recent immunochemical studies (84), no lipid A-like molecules have been characterized by chemical methods in plants. Such molecules might also have been overlooked, if localized to root hairs or stem cells. *Arabidopsis lpxA* can rescue a temperature sensitive *lpxA* mutant of *E. coli*, showing that plant LpxA can catalyze UDP-GlcNAc acylation (83).

3) Can in vitro assays for LPS flipping in membrane vesicles be developed?

The genetic and biochemical evidence for the involvement of proteins such as MsbA (55, 143) and Imp/RlpB (56,60) in catalyzing trans-membrane movement of LPS in cells is very compelling, but it needs to be bolstered by the development of in vitro assays in reconstituted liposomes with purified components. The use of lipid A modification enzymes, like LpxE or PagL, as reporters for the trans-membrane movement of LPS in vitro should be explored, as this promising approach may facilitate development of robust in vitro systems.

4) Can crystal structures of the cytoplasmic membrane proteins involved in lipid A biosynthesis, modification, and signaling be obtained?

A great deal of progress has already been made with soluble proteins like LpxA (91,93) and LpxC (103,107), but the other constitutive enzymes are also of great interest. A structure of TLR4/MD2 with a bound ligand, like Kdo_2-lipid A, should provide important new insights into signaling mechanisms. Methods for crystallizing cytoplasmic membrane proteins have improved in recent years. However, the problems encountered with the structural studies of MsbA show how difficult this approach can be (150,151).

5) Will lipid A-like molecules that block the TLR4/MD2 receptor be useful for the treatment of gram-negative sepsis?

Many clinical trials have failed in the arena of sepsis (25), but the current work with the antagonist E5564 is unique with regard to potency and selectivity of this LPS antagonist in humans (36). Phase III trials are in progress.

6) Can clinically useful antibiotics be developed around the constitutive lipid A pathway?

The best available LpxC inhibitors (Fig. 5A) (102) may be effective enough for clinical trials, pending improvements in bioavailability, pharmacokinetics and toxicology.

7) Can lipid A modification systems be exploited for vaccine development?

Work with *Y. pestis* expressing *lpxL* is the most advanced in this regard (138). The opportunities afforded by attenuated *lpxF* mutants of *F. tularensis* (59,217) or strains lacking *lpxM* (*msbB*)

(135,136) are under active investigation. The properties of *Salmonella* strains expressing LpxE (58), which synthesize the mono-phosphorylated, non-toxic adjuvant form of lipid A, will also be of great interest.

Answers to many of the above questions should emerge from careful studies of the unique proteins and enzymes that assemble and modify lipid A. A combination of genetics and biochemistry will be required to bridge the remaining gaps between lipid A structural diversity and biological function.

ACKNOWLEDGMENTS

References

1. Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH Jr. et al. J. Lipid Res 2005;46:839–62. [PubMed: 15722563]

2. Raetz CRH, Whitfield C. Annu. Rev. Biochem 2002;71:635–700. [PubMed: 12045108]

3. Brade, H.; Opal, SM.; Vogel, SN.; Morrison, DC., editors. Endotoxin in Health and Disease. Marcel Dekker, Inc.; New York: 1999. p. 950

4. Nikaido H. Microbiol. Mol. Biol. Rev 2003;67:593–656. [PubMed: 14665678]

5. Galloway SM, Raetz CRH. J. Biol. Chem 1990;265:6394–402. [PubMed: 2180947]

6. Guan Z, Breazeale SD, Raetz CRH. Anal. Biochem 2005;345:336–9. [PubMed: 16118008]

7. Steeghs L, de Cock H, Evers E, Zomer B, Tommassen J, van der Ley P. Embo J 2001;20:6937–45. [PubMed: 11742971]

8. Meredith TC, Aggarwal P, Mamat U, Lindner B, Woodard RW. ACS Chem. Biol 2006;1:33–42. [PubMed: 17163638]

9. Belunis CJ, Clementz T, Carty SM, Raetz CRH. J. Biol. Chem 1995;270:27646–52. [PubMed: 7499229]

10. Onishi HR, Pelak BA, Gerckens LS, Silver LL, Kahan FM, et al. Science 1996;274:980–2. [PubMed: 8875939]

11. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, et al. Science 1998;282:2085–8. [PubMed: 9851930]

12. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, et al. J. Immunol 1999;162:3749–52. [PubMed: 10201887]

13. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, et al. J. Exp. Med 1999;189:1777–82. [PubMed: 10359581]

14. Gangloff M, Gay NJ. Trends Biochem. Sci 2004;29:294–300. [PubMed: 15276183]

15. Miller SI, Ernst RK, Bader MW. Nat. Rev. Microbiol 2005;3:36–46. [PubMed: 15608698]

16. Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. J. Immunol 2005;175:6465–72. [PubMed: 16272300]

17. Akira S, Uematsu S, Takeuchi O. Cell 2006;124:783–801. [PubMed: 16497588]

18. Beutler B, Cerami A. Annu. Rev. Biochem 1988;57:505–18. [PubMed: 3052281]

19. Dinarello CA. Blood 1991;77:1627–52. [PubMed: 1826616]

20. Medzhitov R, Janeway C Jr. N. Engl. J. Med 2000;343:338–44. [PubMed: 10922424]

21. van Duin D, Medzhitov R, Shaw AC. Trends Immunol 2006;27:49–55. [PubMed: 16310411]

22. Li A, Chang AC, Peer GT, Hinshaw LB, Taylor FB Jr. Shock 1996;5:274–9. [PubMed: 8721387]

23. Drake TA, Cheng J, Chang A, Taylor FB Jr. Am. J. Pathol 1993;142:1458–70. [PubMed: 7684196]

24. Parillo JE. N. Engl. J. Med 1993;328:1471–7. [PubMed: 8479467]

25. Russell JA. N. Engl. J. Med 2006;355:1699–713. [PubMed: 17050894]

26. Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, et al. FASEB Journal 1994;8:217–25. [PubMed: 8119492]

27. Prabhakar U, Conway TM, Murdock P, Mooney JL, Clark S, et al. DNA Cell Biol 2005;24:410–31. [PubMed: 16008510]

28. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, et al. Nature 2005;437:1032–7. [PubMed: 16136080]

29. Qureshi N, Takayama K, Ribi E. J. Biol. Chem 1982;257:11808–15. [PubMed: 6749846]

30. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, et al. Trends Microbiol 2002;10:S32–7. [PubMed: 12377566]

31. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, et al. Expert. Opin. Biol. Ther 2004;4:1129–38. [PubMed: 15268679]

32. Takayama K, Qureshi N, Beutler B, Kirkland TN. Infect. Immun 1989;57:1336–8. [PubMed: 2784418]

33. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CRH. J. Biol. Chem 1991;266:19490–8. [PubMed: 1918061]

34. Christ WJ, Asano O, Robidoux AL, Perez M, Wang Y, et al. Science 1995;265:80–3. [PubMed: 7701344]

35. Hawkins LD, Christ WJ, Rossignol DP. Curr. Top. Med. Chem 2004;4:1147–71. [PubMed: 15279606]

36. Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, et al. J. Infect. Dis 2003;187:631–9. [PubMed: 12599080]

37. Bell JK, Botos I, Hall PR, Askins J, Shiloach J, et al. Proc Natl Acad Sci U S A 2005;102:10976–80. [PubMed: 16043704]

38. Choe J, Kelker MS, Wilson IA. Science 2005;309:581–5. [PubMed: 15961631]

39. Bell JK, Askins J, Hall PR, Davies DR, Segal DM. Proc. Natl. Acad. Sci. U S A 2006;103:8792–7. [PubMed: 16720699]

40. Raetz CRH. Annu. Rev. Biochem 1990;59:129–70. [PubMed: 1695830]

41. Gunn JS, Lim KB, Krueger J, Kim K, Guo L, et al. Mol. Microbiol 1998;27:1171–82. [PubMed: 9570402]

42. Guo L, Lim KB, Gunn JS, Bainbridge B, Darveau RP, et al. Science 1997;276:250–3. [PubMed: 9092473]

43. Groisman EA. J. Bacteriol 2001;183:1835–42. [PubMed: 11222580]

44. Gibbons HS, Kalb SR, Cotter RJ, Raetz CRH. Mol. Microbiol 2005;55:425–40. [PubMed: 15659161]

45. Bader MW, Sanowar S, Daley ME, Schneider AR, Cho U, et al. Cell 2005;122:461–72. [PubMed: 16096064]

46. Bishop RE, Gibbons HS, Guina T, Trent MS, Miller SI, Raetz CRH. Embo J 2000;19:5071–80. [PubMed: 11013210]

47. Trent MS, Ribeiro AA, Lin S, Cotter RJ, Raetz CRH. J. Biol. Chem 2001;276:43122–31. [PubMed: 11535604]

48. Trent MS, Ribeiro AA, Doerrler WT, Lin S, Cotter RJ, Raetz CRH. J. Biol. Chem 2001;276:43132–44. [PubMed: 11535605]

49. Trent MS, Pabich W, Raetz CRH, Miller SI. J. Biol. Chem 2001;276:9083–92. [PubMed: 11108722]

50. Trent MS, Raetz CRH. J. Endotoxin Res 2002;8:158.

51. Tran AX, Karbarz MJ, Wang X, Raetz CRH, McGrath SC, et al. J. Biol. Chem 2004;279:55780–91. [PubMed: 15489235]

52. Lee H, Hsu FF, Turk J, Groisman EA. J. Bacteriol 2004;186:4124–33. [PubMed: 15205413]

53. Reynolds CM, Kalb SR, Cotter RJ, Raetz CRH. J. Biol. Chem 2005;280:21202–11. [PubMed: 15795227]

54. Reynolds CM, Ribeiro AA, McGrath SC, Cotter RJ, Raetz CRH, Trent MS. J. Biol. Chem 2006;281:21974–87. [PubMed: 16704973]

55. Doerrler WT, Gibbons HS, Raetz CRH. J. Biol. Chem 2004;279:45102–9. [PubMed: 15304478]

56. Bos MP, Tefsen B, Geurtsen J, Tommassen J. Proc. Natl. Acad. Sci. U S A 2004;101:9417–22. [PubMed: 15192148]

57. Jia W, Zoeiby AE, Petruzziello TN, Jayabalasingham B, Seyedirashti S, Bishop RE. J. Biol. Chem 2004;279:44966–75. [PubMed: 15319435]

58. Wang X, Karbarz MJ, McGrath SC, Cotter RJ, Raetz CRH. J. Biol. Chem 2004;279:49470–8. [PubMed: 15339914]

59. Wang X, McGrath SC, Cotter RJ, Raetz CRH. J. Biol. Chem 2006;281:9321–30. [PubMed: 16467300]

60. Wu T, McCandlish AC, Gronenberg LS, Chng SS, Silhavy TJ, Kahne D. Proc. Natl. Acad. Sci. U S A 2006;103:11754–9. [PubMed: 16861298]

61. Nishijima M, Raetz CRH. J. Biol. Chem 1979;254:7837–44. [PubMed: 381294]

62. Takayama K, Qureshi N, Mascagni P, Nashed MA, Anderson L, Raetz CRH. J. Biol. Chem 1983;258:7379–85. [PubMed: 6345522]

63. Bulawa CE, Raetz CRH. J. Biol. Chem 1984;259:4846–51. [PubMed: 6370994]

64. Imoto M, Kusumoto S, Shiba T, Naoki H, Iwashita T, et al. Tetrahedron Lett 1983;24:4017–20.

65. Strain SM, Fesik SW, Armitage IM. J. Biol. Chem 1983;258:13466–77. [PubMed: 6358205]

66. Galanos C, Lüderitz O, Rietschel ET, Westphal O, Brade H, et al. Eur. J. Biochem 1985;148:1–5. [PubMed: 2579812]

67. Anderson MS, Bulawa CE, Raetz CRH. J. Biol. Chem 1985;260:15536–41. [PubMed: 3905795]

68. Ray BL, Painter G, Raetz CRH. J. Biol. Chem 1984;259:4852–9. [PubMed: 6370995]

69. Riley M, Abe T, Arnaud MB, Berlyn MK, Blattner FR, et al. Nucleic Acids Res 2006;34:1–9. [PubMed: 16397293]

70. Krziwon C, Zähringer U, Kawahara K, Weidemann B, Kusumoto S, et al. Infect. Immun 1995;63:2899–905. [PubMed: 7542635]

71. Wheeler DL, Church DM, Federhen S, Lash AE, Madden TL, et al. Nucleic Acids Research 2003;31:28–33. [PubMed: 12519941]

72. Anderson MS, Bull HS, Galloway SM, Kelly TM, Mohan S, et al. J. Biol. Chem 1993;268:19858–65. [PubMed: 8366124]

73. Kelly TM, Stachula SA, Raetz CRH, Anderson MS. J. Biol. Chem 1993;268:19866–74. [PubMed: 8366125]

74. Young K, Silver LL, Bramhill D, Cameron P, Eveland SS, et al. J. Biol. Chem 1995;270:30384–91. [PubMed: 8530464]

75. Radika K, Raetz CRH. J. Biol. Chem 1988;263:14859–67. [PubMed: 3049593]

76. Babinski KJ, Kanjilal SJ, Raetz CRH. J. Biol. Chem 2002;277:25947–56. [PubMed: 12000771]

77. Babinski KJ, Ribeiro AA, Raetz CRH. J. Biol. Chem 2002;277:25937–46. [PubMed: 12000770]

78. Garrett TA, Kadrmas JL, Raetz CRH. J. Biol. Chem 1997;272:21855–64. [PubMed: 9268317]

79. Clementz T, Bednarski JJ, Raetz CRH. J. Biol. Chem 1996;271:12095–102. [PubMed: 8662613]

80. Clementz T, Zhou Z, Raetz CRH. J. Biol. Chem 1997;272:10353–60. [PubMed: 9099672]

81. Carty SM, Sreekumar KR, Raetz CRH. J. Biol. Chem 1999;274:9677–85. [PubMed: 10092655]

82. Vorachek-Warren MK, Ramirez S, Cotter RJ, Raetz CRH. J. Biol. Chem 2002;277:14194–205. [PubMed: 11830595]

83. Liu D, Sun TP, Raetz CRH. FASEB J 2003;17(Suppl S):A579–A.Part1

84. Armstrong MT, Theg SM, Braun N, Wainwright N, Pardy RL, Armstrong PB. Faseb. J 2006;20:2145–6. [PubMed: 16935939]

85. Anderson MS, Raetz CRH. J. Biol. Chem 1987;262:5159–69. [PubMed: 3549716]

86. Williamson JM, Anderson MS, Raetz CRH. J. Bacteriol 1991;173:3591–6. [PubMed: 1904441]

87. Wyckoff TJO, Lin S, Cotter RJ, Dotson GD, Raetz CRH. J. Biol. Chem 1998;273:32369–72. [PubMed: 9829962]

88. Odegaard TJ, Kaltashov IA, Cotter RJ, Steeghs L, van der Ley P, et al. J. Biol. Chem 1997;272:19688–96. [PubMed: 9242624]

89. Sweet CR, Williams AH, Karbarz MJ, Werts C, Kalb SR, et al. J. Biol. Chem 2004;279:25411–9. [PubMed: 15044493]

90. Dotson GD, Kaltashov IA, Cotter RJ, Raetz CRH. J. Bacteriol 1998;180:330–7. [PubMed: 9440522]

91. Raetz CRH, Roderick SL. Science 1995;270:997–1000. [PubMed: 7481807]

92. Lee BI, Suh SW. Proteins 2003;53:772–4. [PubMed: 14579368]

93. Williams AH, Immormino RM, Gewirth DT, Raetz CRH. Proc. Natl. Acad. Sci. U S A 2006:10877–82. [PubMed: 16835299]

94. Wyckoff TJ, Raetz CRH. J. Biol. Chem 1999;274:27047–55. [PubMed: 10480918]

95. Sweet CR, Ribeiro AA, Raetz CRH. J. Biol. Chem 2004;279:25400–10. [PubMed: 15044494]

96. Que-Gewirth NLS, Ribeiro AA, Kalb SR, Cotter RJ, Bulach DM, et al. J. Biol. Chem 2004;279:25420–9. [PubMed: 15044492]

97. Anderson MS, Robertson AD, Macher I, Raetz CRH. Biochemistry 1988;27:1908–17. [PubMed: 3288280]

98. Jackman JE, Raetz CRH, Fierke CA. Biochemistry 1999;38:1902–11. [PubMed: 10026271]

99. Jackman JE, Raetz CRH, Fierke CA. Biochemistry 2001;40:514–23. [PubMed: 11148046]

100. Jackman JE, Fierke CA, Tumey LN, Pirrung M, Uchiyama T, et al. J. Biol.Chem 2000;275:11002–9. [PubMed: 10753902]

101. Clements JM, Coignard F, Johnson I, Chandler S, Palan S, et al. Antimicrob. Agents Chemother 2002;46:1793–9. [PubMed: 12019092]

102. McClerren AL, Endsley S, Bowman JL, Andersen NH, Guan Z, et al. Biochemistry 2005;44:16574–83. [PubMed: 16342948]

103. Whittington DA, Rusche KM, Shin H, Fierke CA, Christianson DW. Proc. Natl. Acad. Sci. U S A 2003;100:8146–50. [PubMed: 12819349]

104. Hernick M, Gennadios HA, Whittington DA, Rusche KM, Christianson DW, Fierke CA. J. Biol. Chem 2005;280:16969–78. [PubMed: 15705580]

105. Gennadios HA, Whittington DA, Li X, Fierke CA, Christianson DW. Biochemistry 2006;45:7940–8. [PubMed: 16800620]

106. Gennadios HA, Christianson DW. Biochemistry 2006;45:15216–23. [PubMed: 17176043]

107. Coggins BE, Li X, McClerren AL, Hindsgaul O, Raetz CRH, Zhou P. Nat. Struct. Biol 2003;10:645–51. [PubMed: 12833153]

108. Coggins BE, McClerren AL, Jiang L, Li X, Rudolph J, et al. Biochemistry 2005;44:1114–11126. [PubMed: 15667205]

109. Sorensen PG, Lutkenhaus J, Young K, Eveland SS, Anderson MS, Raetz CRH. J. Biol. Chem 1996;271:25898–905. [PubMed: 8824222]

110. Fuhrer F, Langklotz S, Narberhaus F. Mol. Microbiol 2006;59:1025–36. [PubMed: 16420369]

111. Ogura T, Inoue K, Tatsuta T, Suzaki T, Karata K, et al. Mol. Microbiol 1999;31:833–44. [PubMed: 10048027]

112. Hu Y, Chen L, Ha S, Gross B, Falcone B, et al. Proc. Natl. Acad. Sci. U S A 2003;100:845–9. [PubMed: 12538870]

113. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. NucleicAcids Research 1997;25:3389–402.

114. Haselberger A, Hildebrandt J, Lam C, Liehl E, Loibner H, et al. Triangle 1987;26:33–49.

115. Scholz D, Bednarik K, Ehn G, Neruda W, Janzek E, et al. J. Med. Chem 1992;35:2070–4. [PubMed: 1597857]

116. Albers U, Reus K, Shuman HA, Hilbi H. Microbiology 2005;151:167–82. [PubMed: 15632436]

117. Garrett TA, Que NL, Raetz CRH. J. Biol. Chem 1998;273:12457–65. [PubMed: 9575203]

118. Belunis CJ, Raetz CRH. J. Biol. Chem 1992;267:9988–97. [PubMed: 1577828]

119. Clementz T, Raetz CRH. J. Biol. Chem 1991;266:9687–96. [PubMed: 2033061]

120. Brozek KA, Raetz CRH. J. Biol. Chem 1990;265:15410–7. [PubMed: 2203778]

121. Ray BL, Raetz CRH. J. Biol. Chem 1987;262:1122–8. [PubMed: 3027079]

122. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, et al. J. Clin. Invest 2000;105:497–504. [PubMed: 10683379]

123. Poltorak A, Ricciardi-Castagnoli P, Citterio S, Beutler B. Proc. Natl. Acad. Sci. U S A 2000;97:2163–7. [PubMed: 10681462]

124. Saitoh S, Akashi S, Yamada T, Tanimura N, Kobayashi M, et al. Int. Immunol 2004;16:961–9. [PubMed: 15184344]

125. Brozek KA, Hosaka K, Robertson AD, Raetz CRH. J. Biol. Chem 1989;264:6956–66. [PubMed: 2651435]

126. Meredith TC, Woodard RW. J Biol Chem 2003;278:32771–7. [PubMed: 12805358]

127. Sperandeo P, Pozzi C, Deho G, Polissi A. Res. Microbiol 2006;157:547–58. [PubMed: 16765569]

128. White KA, Kaltashov IA, Cotter RJ, Raetz CRH. J. Biol. Chem 1997;272:16555–63. [PubMed: 9195966]

129. White KA, Lin S, Cotter RJ, Raetz CR. J. Biol. Chem 1999;274:31391–400. [PubMed: 10531340]

130. Brabetz W, Muller-Loennies S, Brade H. J. Biol. Chem 2000;275:34954–62. [PubMed: 10952982]

131. Isobe T, White KA, Allen AG, Peacock M, Raetz CRH, Maskell DJ. J. Bacteriol 1999;181:2648–51. [PubMed: 10198035]

132. Belunis CJ, Mdluli KE, Raetz CRH, Nano FE. J. Biol. Chem 1992;267:18702–7. [PubMed: 1382060]

133. Karow M, Georgopoulos C. J. Bacteriol 1992;174:702–10. [PubMed: 1732206]

134. Somerville JE Jr. Cassiano L, Bainbridge B, Cunningham MD, Darveau RP. J. Clin. Invest 1996;97:359–65. [PubMed: 8567955]

135. Low KB, Ittensohn M, Le T, Platt J, Sodi S, et al. Nat. Biotechnol 1999;17:37–41. [PubMed: 9920266]

136. D'Hauteville H, Khan S, Maskell DJ, Kussak A, Weintraub A, et al. J. Immunol 2002;168:5240–51. [PubMed: 11994481]

137. Vorachek-Warren MK, Carty SM, Lin S, Cotter RJ, Raetz CRH. J. Biol. Chem 2002;277:14186–93. [PubMed: 11830594]

138. Montminy SW, Khan N, McGrath S, Walkowicz MJ, Sharp F, et al. Nat. Immunol 2006;7:1066–73. [PubMed: 16980981]

139. Ferguson AD, Hofmann E, Coulton JW, Diederichs K, Welte W. Science 1998;282:2215–20. [PubMed: 9856937]

140. Ferguson AD, Welte W, Hofmann E, Lindner B, Holst O, et al. Structure Fold. Des 2000;8:585–92. [PubMed: 10873859]

141. Nishiyama K, Ikegami A, Moser M, Schiltz E, Tokuda H, Muller M. J. Biol.Chem 2006;281:35667–76. [PubMed: 17008318]

142. Steeghs L, den Hartog R, den Boer A, Zomer B, Roholl P, van der Ley P. Nature 1998;392:449–50. [PubMed: 9548250]

143. Doerrler WT, Reedy MC, Raetz CRH. J. Biol. Chem 2001;276:11461–4. [PubMed: 11278265]

144. Karow M, Georgopoulos C. Mol. Microbiol 1993;7:69–79. [PubMed: 8094880]

145. Polissi A, Georgopoulos C. Mol. Microbiol 1996;20:1221–33. [PubMed: 8809774]

146. Zhou Z, White KA, Polissi A, Georgopoulos C, Raetz CRH. J. Biol. Chem 1998;273:12466–75. [PubMed: 9575204]

147. Chang G, Roth CB. Science 2001;293:1793–800. [PubMed: 11546864]

148. Chang G. J. Mol. Biol 2003;330:419–30. [PubMed: 12823979]

149. Reyes CL, Chang G. Science 2005;308:1028–31. [PubMed: 15890884]

150. Dawson RJ, Locher KP. Nature 2006;443:180–5. [PubMed: 16943773]

151. Chang G, Roth CB, Reyes CL, Pornillos O, Chen Y-J, Chen AP. Science 2006;314:1875. [PubMed: 17185584]

152. Raetz CRH, Garrett TA, Reynolds CM, Shaw WA, Moore JD, et al. J. Lipid Res 2006;47:1097–111. [PubMed: 16479018]

153. Huijbregts RP, de Kroon AI, de Kruijff B. J. Biol. Chem 1998;273:18936–42. [PubMed: 9668071]

154. Doerrler WT, Raetz CRH. J. Biol. Chem 2002;277:36697–705. [PubMed: 12119303]

155. Kol MA, van Dalen A, de Kroon AI, de Kruijff B. J. Biol. Chem 2003;278:24586–93. [PubMed: 12714595]

156. Venter JC, Remington K, Heidelberg JF, Halpern AL, Rusch D, et al. Science 2004;304:66–74. [PubMed: 15001713]

157. Osborn MJ, Rick PD, Rasmussen NS. J. Biol. Chem 1980;255:4246–51. [PubMed: 6989833]

158. Tefsen B, Bos MP, Beckers F, Tommassen J, de Cock H. J. Biol. Chem 2005;280:35961–6. [PubMed: 16123038]

159. Sperandeo P, Cescutti R, Villa R, Di Benedetto C, Candia D, et al. J. Bacteriol 2007;189:244–53. [PubMed: 17056748]

160. Braun M, Silhavy TJ. Mol. Microbiol 2002;45:1289–302. [PubMed: 12207697]

161. Borst P, Zelcer N, van Helvoort A. Biochim. Biophys. Acta 2000;1486:128–44. [PubMed: 10856718]

162. Borst P, Elferink RO. Annu. Rev. Biochem 2002;71:537–92. [PubMed: 12045106]

163. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, et al. Cell 1993;75:451–62. [PubMed: 8106172]

164. Schmitz G, Liebisch G, Langmann T. FEBS Lett 2006;580:5597–610. [PubMed: 16934254]

165. Zhou Z, Lin S, Cotter RJ, Raetz CRH. J. Biol. Chem 1999;274:18503–14. [PubMed: 10373459]

166. Zhou Z, Ribeiro AA, Lin S, Cotter RJ, Miller SI, Raetz CRH. J. Biol. Chem 2001;276:43111–21. [PubMed: 11535603]

167. Brozek KA, Bulawa CE, Raetz CRH. J. Biol. Chem 1987;262:5170–9. [PubMed: 3549717]

168. Guo L, Lim KB, Poduje CM, Daniel M, Gunn JS, et al. Cell 1998;95:189–98. [PubMed: 9790526]

169. Helander IM, Kilpeläinen I, Vaara M. Mol. Microbiol 1994;11:481–7. [PubMed: 8152372]

170. Nummila K, Kilpeläinen I, Zähringer U, Vaara M, Helander IM. Mol. Microbiol 1995;16:271–8. [PubMed: 7565089]

171. Helander IM, Kato Y, Kilpelainen I, Kostiainen R, Lindner B, et al. Eur. J. Biochem 1996;237:272–8. [PubMed: 8620884]

172. Breazeale SD, Ribeiro AA, Raetz CRH. J. Biol. Chem 2002;277:2886–96. [PubMed: 11706007]

173. Breazeale SD, Ribeiro AA, Raetz CRH. J. Biol. Chem 2003;279:24731–9. [PubMed: 12704196]

174. Breazeale SD, Ribeiro AA, McClerren AL, Raetz CRH. J. Biol. Chem 2005;280:14154–67. [PubMed: 15695810]

175. Williams GJ, Breazeale SD, Raetz CRH, Naismith JH. J. Biol. Chem 2005;280:23000–8. [PubMed: 15809294]

176. Gatzeva-Topalova PZ, May AP, Sousa MC. Structure (Camb) 2005;13:929–42. [PubMed: 15939024]

177. Noland BW, Newman JM, Hendle J, Badger J, Christopher JA, et al. Structure (Camb) 2002;10:1569–80. [PubMed: 12429098]

178. Gunn JS, Ryan SS, Van Velkinburgh JC, Ernst RK, Miller SI. Infect. Immun 2000;68:6139–46. [PubMed: 11035717]

179. Kanipes MI, Lin S, Cotter RJ, Raetz CRH. J. Biol. Chem 2001;276:1156–63. [PubMed: 11042192]

180. Figueroa-Bossi N, Lemire S, Maloriol D, Balbontin R, Casadesus J, Bossi L. Mol. Microbiol 2006;62:838–52. [PubMed: 16999834]

181. Tamayo R, Choudhury B, Septer A, Merighi M, Carlson R, Gunn JS. J. Bacteriol 2005;187:3391–9. [PubMed: 15866924]

182. Kim SH, Jia W, Parreira VR, Bishop RE, Gyles CL. Microbiology 2006;152:657–66. [PubMed: 16514146]

183. Kim SH, Jia W, Bishop RE, Gyles C. Infect. Immun 2004;72:1174–80. [PubMed: 14742570]

184. Kaniuk NA, Vinogradov E, Li J, Monteiro MA, Whitfield C. J. Biol. Chem 2004;279:31237–50. [PubMed: 15155763]

185. El Ghachi M, Derbise A, Bouhss A, Mengin-Lecreulx D. J. Biol. Chem 2005;280:18689–95. [PubMed: 15778224]

186. Lazar K, Walker S. Curr. Opin. Chem. Biol 2002;6:786–93. [PubMed: 12470732]

187. Cho US, Bader MW, Amaya MF, Daley ME, Klevit RE, et al. J. Mol. Biol 2006;356:1193–206. [PubMed: 16406409]

188. Martin-Orozco N, Touret N, Zaharik ML, Park E, Kopelman R, et al. Mol. Biol. Cell 2006;17:498–510. [PubMed: 16251362]

189. Winfield MD, Groisman EA. Proc. Natl. Acad. Sci. U S A 2004;101:17162–7. [PubMed: 15569938]

190. Guina T, Yi EC, Wang H, Hackett M, Miller SI. J. Bacteriol 2000;182:4077–86. [PubMed: 10869088]

191. Robey M, O'Connell W, Cianciotto NP. Infect. Immun 2001;69:4276–86. [PubMed: 11401964]

192. Preston A, Maxim E, Toland E, Pishko EJ, Harvill ET, et al. Mol. Microbiol 2003;48:725–36. [PubMed: 12694617]

193. Pilione MR, Pishko EJ, Preston A, Maskell DJ, Harvill ET. Infect. Immun 2004;72:2837–42. [PubMed: 15102794]

194. Bishop RE. Mol. Microbiol 2005;57:900–12. [PubMed: 16091033]

195. Rebeil R, Ernst RK, Gowen BB, Miller SI, Hinnebusch BJ. Mol. Microbiol 2004;52:1363–73. [PubMed: 15165239]

196. Ahn VE, Lo EI, Engel CK, Chen L, Hwang PM, et al. Embo. J 2004;23:2931–41. [PubMed: 15272304]

197. Hwang PM, Choy WY, Lo EI, Chen L, Forman-Kay JD, et al. Proc. Natl. Acad. Sci. U S A 2002;99:13560–5. [PubMed: 12357033]

198. Evanics F, Hwang PM, Cheng Y, Kay LE, Prosser RS. J. Am. Chem. Soc 2006;128:8256–64. [PubMed: 16787090]

199. Stover AG, Da Silva Correia J, Evans JT, Cluff CW, Elliott MW, et al. J. Biol. Chem 2004;279:4440–09. [PubMed: 14570885]

200. Hwang PM, Bishop RE, Kay LE. Proc. Natl. Acad. Sci. U S A 2004;101:9618–23. [PubMed: 15210985]

201. Tam C, Missiakas D. Mol. Microbiol 2005;55:1403–12. [PubMed: 15720549]

202. Gibbons HS, Lin S, Cotter RJ, Raetz CRH. J. Biol. Chem 2000;275:32940–9. [PubMed: 10903325]

203. Raetz CRH. J. Endotoxin Res 2001;7:73–8. [PubMed: 11521087]

204. Kawasaki K, Ernst RK, Miller SI. J. Bacteriol 2005;187:2448–57. [PubMed: 15774888]

205. Geurtsen J, Steeghs L, Hamstra HJ, Ten Hove J, de Haan A, et al. Infect. Immun 2006;74:5574–85. [PubMed: 16988232]

206. Kawasaki K, Ernst RK, Miller SI. J. Biol. Chem 2004;279:20044–8. [PubMed: 15014080]

207. Ernst RK, Adams KN, Moskowitz SM, Kraig GM, Kawasaki K, et al. J. Bacteriol 2006;188:191–201. [PubMed: 16352835]

208. Geurtsen J, Steeghs L, Hove JT, van der Ley P, Tommassen J. J. Biol. Chem 2005;280:8248–59. [PubMed: 15611102]

209. Rutten L, Geurtsen J, Lambert W, Smolenaers JJ, Bonvin AM, et al. Proc. Natl. Acad. Sci. U S A 2006;103:7071–6. [PubMed: 16632613]

210. Ellis J, Oyston PC, Green M, Titball RW. Clin. Microbiol. Rev 2002;15:631–46. [PubMed: 12364373]

211. Kieffer TL, Cowley S, Nano FE, Elkins KL. Microbes Infect 2003;5:397–403. [PubMed: 12737995]

212. Wang X, Ribeiro AA, Guan Z, McGrath S, Cotter R, Raetz CRH. Biochemistry 2006;45:14427–40. [PubMed: 17128982]

213. Larsson P, Oyston PC, Chain P, Chu MC, Duffield M, et al. Nat. Genet 2005;37:153–9. [PubMed: 15640799]

214. Stead C, Tran A, Ferguson D Jr. McGrath S, Cotter R, Trent S. J. Bacteriol 2005;187:3374–83. [PubMed: 15866922]

215. Phillips NJ, Schilling B, McLendon MK, Apicella MA, Gibson BW. Infect. Immun 2004;72:5340–8. [PubMed: 15322031]

216. Vinogradov E, Perry MB, Conlan JW. Eur. J. Biochem 2002;269:6112–8. [PubMed: 12473106]

217. Wang X, Ribeiro AA, Guan Z, Abraham SN, Raetz CRH. Proc. Natl. Acad. Sci. U S A. 2007in press

218. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, et al. Nature 1997;388:539–47. [PubMed: 9252185]

219. Bhat UR, Forsberg LS, Carlson RW. J. Biol. Chem 1994;269:14402–10. [PubMed: 8182046]

220. Que NLS, Lin S, Cotter RJ, Raetz CRH. J. Biol. Chem 2000;275:28006–16. [PubMed: 10856303]

221. Que NLS, Ribeiro AA, Raetz CRH. J. Biol. Chem 2000;275:28017–27. [PubMed: 10856304]

222. Bhat UR, Mayer H, Yokota A, Hollingsworth RI, Carlson R. J. Bacteriol 1991;173:2155–9. [PubMed: 2007543]

223. Basu SS, White KA, Que NL, Raetz CRH. J. Biol. Chem 1999;274:11150–8. [PubMed: 10196200]

224. Carlson RW, Reuhs B, Chen TB, Bhat UR, Noel KD. J. Biol. Chem 1995;270:11783–8. [PubMed: 7538123]

225. Brozek KA, Kadrmas JL, Raetz CRH. J. Biol. Chem 1996;271:32112–8. [PubMed: 8943264]

226. Price NPJ, Kelly TM, Raetz CRH, Carlson RW. J. Bacteriol 1994;176:4646–55. [PubMed: 8045896]

227. Basu SS, Karbarz MJ, Raetz CRH. J. Biol. Chem 2002;277:28959–71. [PubMed: 12019272]

228. Brozek KA, Carlson RW, Raetz CRH. J. Biol. Chem 1996;271:32126–36. [PubMed: 8943266]

229. Karbarz MJ, Kalb SR, Cotter RJ, Raetz CRH. J. Biol. Chem 2003;278:39269–79. [PubMed: 12869541]

230. Que-Gewirth NLS, Lin S, Cotter RJ, Raetz CRH. J. Biol. Chem 2003;278:12109–19. [PubMed: 12531907]

231. Que-Gewirth NLS, Karbarz MJ, Kalb SR, Cotter RJ, Raetz CRH. J. Biol. Chem 2003;278:12120–9. [PubMed: 12531908]

232. Kanjilal-Kolar S, Basu SS, Kanipes MI, Guan Z, Garrett TA, Raetz CRH. J. Biol. Chem 2006;281:12865–78. [PubMed: 16497674]

233. Kanjilal-Kolar S, Raetz CRH. J. Biol. Chem 2006;281:12879–87. [PubMed: 16497671]

234. Ferguson GP, Datta A, Carlson RW, Walker GC. Mol. Microbiol 2005;56:68–80. [PubMed: 15773979]

235. Vedam V, Kannenberg EL, Haynes JG, Sherrier DJ, Datta A, Carlson RW. J. Bacteriol 2003;185:1841–50. [PubMed: 12618448]

236. Boon Hinckley M, Reynolds CM, Ribeiro AA, McGrath SC, Cotter RJ, et al. J. Biol. Chem 2005;280:30214–24. [PubMed: 15994324]

237. Vinogradov EV, Muller-Loennies S, Petersen BO, Meshkov S, Thomas-Oates JE, et al. Eur. J. Biochem 1997;247:82–90. [PubMed: 9249012]

238. Bode CE, Brabetz W, Brade H. Eur. J. Biochem 1998;254:404–12. [PubMed: 9660198]

239. Schneider JE, Reinhold V, Rumley MK, Kennedy EP. J. Biol. Chem 1979;254:10135–8. [PubMed: 385596]

240. Kennedy, EP. Escherichia coli and Salmonella typhimurium. Neidhardt, FC., editor. I. ASM Publications; Washington, D. C: 1987. p. 672-9.

241. Wu, HC. Escherichia coli and Salmonella: Cellular and Molecular Biology. Neidhardt, FC., editor. American Society for Microbiology; Washington, D. C.: 1996. p. 1005-14.

242. Raetz CRH. Annu. Rev. Genet 1986;20:253–95. [PubMed: 3545060]

243. Cronan JE. Annu. Rev. Microbiol 2003;57:203–24. [PubMed: 14527277]

244. Stevenson G, Neal B, Liu D, Hobbs M, Packer NH, et al. J. Bacteriol 1994;176:4144–56. [PubMed: 7517391]

245. Murphy RC, Raetz CRH, Reynolds CM, Barkley RM. Prostaglandins Other Lipid Mediat 2005;77:131–40. [PubMed: 16099398]

246. Jain NU, Wyckoff TJ, Raetz CRH, Prestegard JH. J. Mol. Biol 2004;343:1379–89. [PubMed: 15491619]

247. Feldman MF, Marolda CL, Monteiro MA, Perry MB, Parodi AJ, Valvano MA. J. Biol. Chem 1999;274:35129–38. [PubMed: 10574995]

248. Strain SM, Armitage IM, Anderson L, Takayama K, Qureshi N, Raetz CRH. J. Biol. Chem 1985;260:16089–98. [PubMed: 3905805]

249. Zhou Z, Ribeiro AA, Raetz CRH. J. Biol. Chem 2000;275:13542–51. [PubMed: 10788469]

250. Price NJP, Jeyaretnam B, Carlson RW, Kadrmas JL, Raetz CRH, Brozek KA. Proc. Natl. Acad. Sci. U. S. A 1995;92:7352–6. [PubMed: 7638195]

251. Kadrmas JL, Brozek KA, Raetz CRH. J. Biol. Chem 1996;271:32119–25. [PubMed: 8943265]

252. Kadrmas JL, Allaway D, Studholme RE, Sullivan JT, Ronson CW, et al. J. Biol. Chem 1998;273:26432–40. [PubMed: 9756877]

Figure 1. Schematic structure of the *E. coli* K-12 cell envelope
The structure and biosynthesis of LPS (2,3), peptidoglycan (186), membrane-derived oligosaccharides (239,240), lipoproteins (241) and phospholipids (242,243) are reviewed elsewhere. Strains of *E. coli* K-12 normally do not make O-antigen, unless a mutation in the O-antigen operon is corrected (244). The Kdo_2-lipid A region of LPS (the topic of this review) usually represent the minimal substructure required for growth of gram-negative bacteria. Exceptions include some spirochetes and strains of *Sphinogmonas*, in which the lipid A biosynthesis genes are absent, and *Neisseria meningitidis* in which *lpxA* knockouts lacking LPS are viable (142). If the ABC transporter MsbA (the inner membrane flippase for LPS) is over-expressed, *E. coli* can grow without Kdo (8). These strains still make the tetra-acylated precursor lipid IV_A, which is nevertheless required for growth (8). The *red* phospholipids represent phosphatidylethanolamine and the *yellow* phosphatidylglycerol. Abbreviations: LPS, lipopolysaccharide; MDO, membrane-derived oligosaccharides; PPEtn, ethanolamine pyrophosphate.

Figure 2. The constitutive pathway for Kdo$_2$-lipid A biosynthesis in *E. coli*
Each enzyme of the constitutive lipid A pathway is encoded by a single structural gene (2, 69). The glucosamine disaccharide backbone of lipid A is *blue*. The Kdo disaccharide is *black*. LpxA, C and D are soluble cytoplasmic proteins, whereas LpxH and B are peripheral membrane proteins (2). The distal enzymes of the pathway, starting with LpxK, are integral inner membrane proteins, the active sites of which face the cytoplasm (2). The *red* numbers specify the glucosamine ring positions of lipid A and its precursors. The *black* numbers indicate the predominant fatty acid chain lengths found in *E. coli* lipid A. The single molecular species shown at the bottom left represents about 90 % of the total lipid A in *E. coli*, with most of the rest bearing a C12 secondary acyl chain at position 3′ (152). Additional minor acyl chain variants can be detected by high-resolution mass spectrometry (245).

Figure 3. Structure of free LpxA and of LpxA with bound UDP-(3-*O*-acyl)-GlcNAc
The LpxA homotrimer was solved at 2.6 Å (pdb 1LXA) in the absence of bound ligands (91).
Each subunit has its own color. The side view (*left*) highlights the β-helix domain (91). The
LpxA homotrimer was co-crystallized with a ~25 fold molar excess of UDP-3-*O*-(*R* -3-
hydroxydecanoyl)-GlcNAc and solved at 1.8 Å (Williams and Raetz, in preparation). The top-
down view of this complex (*right*) reveals the location of the active site and the positioning of
the acyl chain, consistent with previous proposals based on site-directed mutagenesis and NMR
studies (94,246).

Figure 4. Biosynthesis and acylation of UDP-GlcNAc3N in *L. interrogans*
The sugar nucleotide UDP-GlcNAc3N is synthesized in two reactions from UDP-GlcNAc.
The intermediate ketone has not yet been characterized, but UDP-GlcNAc3N generated in vitro
by GnnA and GnnB can be isolated in mg quantities (89,95). LpxA from *L. interrogans* is 41
% identical to *E. coli* LpxA at the protein level, and its x-ray structure has recently been
determined (Williams and Raetz, in preparation). *L. interrogans* LpxA does not catalyze the
acylation of UDP-GlcNAc and is absolutely selective for C12 hydroxyacyl chains (89,95).

A.

CHIR-090

$K_i \sim 2$ nM and slow, tight-binding

B.

TU-514

$K_i \sim 650$ nM

Figure 5. Structures of LpxC inhibitors CHIR-090 and TU-514
A. The slow, tight-binding inhibitor CHIR-090 inhibits diverse LpxC orthologues in the low nM range and displays potent antibiotic activity against many gram-negative bacteria (102). **B.** The substrate mimetic TU-514 inhibits *E. coli* LpxC with $K_i \sim$ 650 nM but has little or no antibiotic activity (100).

Figure 6. NMR structure of LpxC with bound substrate-mimetic inhibitor TU-514
This ribbon diagram is based on the NMR studies of Coggins *et al.* (107,108). The recent crystal structure of the same complex is similar, except for slight differences in the orientation of the tetrahydropyran ring (105).

Figure 7. Proteins implicated in O-antigen assembly and in the export of LPS
The proteins in *red* letters are involved in the export of LPS. The ABC transporter MsbA flips newly-synthesized core-lipid A to the outer surface of the inner membrane (55,143). O-antigen is assembled separately on undecaprenyl phosphate and is flipped by the putative transporter Wzx (247). O-antigen oligosaccharides are polymerized on the periplasmic surface of the inner membrane by Wzy and Wzz, and transferred to nascent core-lipid A by WaaL (2). In vitro systems for the polymerase and ligase have not been reported. The periplasmic protein LptA (159) is proposed to shuttle LPS to the essential outer membrane protein complex Imp/RlpB, which is required the assembly of LPS into the outer surface of the outer membrane, as judged by accessibility to the ecto-enzymes PagL or PagP (56,60,197,209). With the exception of the lipid-activated ATPase activity of MsbA (154), no in vitro assays have been developed for any of the proposed transporters. The LptA protein may function together with an additional ABC transporter protein termed LptB and the putative trans-membrane protein YrbK (159).

Figure 8. Covalent modifications of Kdo$_2$-lipid A in *E. coli* K-12 and *Salmonella*

The known covalent modifications of Kdo$_2$-lipid A (3) are indicated by the substituents with the dashed bonds. The glucosamine disaccharide is *blue*, the L-Ara4N unit *green*, and the phosphoethanolamine moieties *red*. Under some conditions, the positions of the phosphoethanolamine and L-Ara4N substituents are reversed (not shown) (248,249). Lipid A species with two phosphoethanolamine units or two L-Ara4N moieties may also be present (44). Expression of the enzymes ArnT (47) and EptA(PmrC) is under the control of PmrA/B (50,52). PagP and PagL are regulated by PhoP/Q (46,47). LpxO (*magenta*), LpxR and EptB are not regulated by either PhoP/Q or PmrA/B (44,53,54). *Asterisks* indicate modification enzymes not found in *E. coli* K-12. Transfer of the *Salmonella* genes encoding these enzymes to *E. coli* results in the expected lipid A modifications.

Figure 9. Biosynthesis of the L-Ara4N unit and its attachment to lipid A

Formation of the L-Ara4N moiety begins with the oxidation of UDP-glucose to UDP-glucuronic acid (172), as first proposed by Zhou et al. (165) Next, the *C*-terminal domain of ArnA catalyzes an NAD$^+$-dependent oxidative decarboxylation to yield an unusual UDP-4-ketopentose, which is converted to UDP-L-Ara4N (*green* moiety) by the transaminase ArnB (173). The *N*-terminal domain of ArnA then uses *N*-10-formyltetrahydrofolate to add a formyl group (*magenta*) to UDP-L-Ara4N (174). Next, ArnC/PmrF, a distant orthologue of dolichyl phosphate-mannose synthase, selectively transfers the formylated L-Ara4N residue to undecaprenyl phosphate (174). The ArnD-dependent deformylation of this lipid to undecaprenyl phosphate-α-L-Ara4N (which accumulates in polymyxin-resistant mutants) likely occurs on the inner leaflet of the inner membrane and may prevent reversal of the ArnC reaction (174). After transport to the outer surface of the inner membrane by a process that may involve the inner membrane proteins ArnE and ArnF (Yan and Raetz, in preparation), the polytopic membrane protein ArnT transfers the L-Ara4N moiety (shown as a *green* rectangle) to lipid A. Given the dual function the ArnA holoenzyme (174-176), the possibility of substrate channeling from ArnA to ArnC deserves consideration. However, ArnA and ArnB do not associate with each other in vitro.

Figure 10. Structure of undecaprenyl phosphate-α-L-Ara4N
This lipid accumulates in polymyxin-resistant mutants of *E. coli* and *Salmonella* (48).

Figure 11. The outer membrane lipid A palmitoyltransferase PagP (*left*) and the lipid A 3-*O*-deacylase PagL (*right*)

The disordered loop connecting the first and second β-strands of PagP (pdb 1THQ), and the bound lipid X with PagL (pdb 2ERV) were introduced subsequently and energy minimized. The authors thank Chris Neale and Régis Pomès (University of Toronto) and Lucy Rutten and Jan Tommassen (Utrecht University) for providing the coordinates of energy minimized PagP and PagL, respectively. Abbreviation: LDAO, lauroyldimethylamine-*N*-oxide.

Figure 12. Extracellular covalent modifications of lipid A in *F. tularensis*
The proposed modification pathway is based on the genetic characterization of the two phosphatases, LpxE and LpxF (58,59), which are present in many bacteria that synthesize phosphate-deficient lipid A. The attachment of galactosamine to *F. tularensis* lipid A involves a polyisoprene phosphate donor, analogous to undecaprenyl phosphate-L-Ara4N in *E. coli* (Wang and Raetz, in preparation). The *F. tularensis* system is also unusual in that much of its lipid A is "free", i.e. not covalently attached to LPS (212). The origin and function of free lipid A have not been established.

Kdo₂-lipid IV_A   **Components B and C**   **Components D and E**


Figure 13. Kdo₂-lipid IV_A versus mature lipid A of *R. etli* and *R. leguminosarum*
These bacteria make phosphate-deficient lipid A molecules from Kdo₂-lipid IV_A (226,250), using the lipid A phosphatases LpxE and LpxF, as described in the text. Lipid A molecules of *Rhizobium* typically contain a very long secondary acyl chain at position 2′ (222). Additional unique features include the presence of galacturonic acid (*cyan*) in place of phosphate at position 4′ and oxidation of the proximal glucosamine unit (*blue*) in a portion of the molecules to aminogluconate (*magenta*) (219-221). Partial substituents and micro-heterogeneity of acyl chains lengths are indicated by *dashed* bonds. Components C and E lack the 3-O linked hydroxyacyl chain. The schematic representations of these structures are shown below the actual chemical structures.

Figure 14. Kdo$_2$-lipid IV$_A$ processing in *R. etli* and *R. leguminosarum* membranes
The processing enzymes unique to the *Rhizbium* system can be assayed using *E. coli* Kdo$_2$-lipid IV$_A$ as the model substrate (223,225,227-229,232,233,250-252). The enzymes that have been characterized to date are labeled in *red* according to the genes that encode them. Other colors: glucosamine, *blue*; galacturonic acid, *cyan*; aminogluconate, *magenta*; Kdo, *white*; other core sugars, *black* dashed line; fatty acids, *green*.

Figure 15. Topography of lipid A modifications in *R. etli* and *R. leguminosarum*
The proposed topography of the processing enzymes is based on the finding that lipid A dephosphorylation by LpxE and LpxF requires a functional *msbA* gene, when foreign *lpxE* or *lpxF* genes are expressed in *E. coli* (51,58,59). The Rgt proteins require a polyisoprene donor as their co-substrate, consistent with a periplasmic localization (232,233). PagL and LpxQ are known to be outer membrane proteins (47,231). The x-ray structure of PagL shows that its active site is oriented towards the outside (209). The orientation of LpxQ is unknown (231). PagP is not present in *Rhizobium*. Enzymes are indicated in *red*, and putative transport proteins are shown in *black*. Letters in the outer membrane refer to lipid A components B, C, D and E, shown in Fig. 13. Other colors: glucosamine, *blue*; galacturonic acid, *cyan*; aminogluconate, *magenta*; Kdo, *white*; other core sugars, *black* dashed line; fatty acids, *green*.